- Trials with a EudraCT protocol (184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
184 result(s) found for: Calcium imaging.
Displaying page 1 of 10.
EudraCT Number: 2021-001730-19 | Sponsor Protocol Number: v1-2 | Start Date*: 2022-02-24 |
Sponsor Name:Medical Univerity of Vienna | ||
Full Title: Hormones and Muscle – Unravelling the metabolic pathways of endocrine myopathies A translational magnetic resonance spectroscopy and imaging pilot study | ||
Medical condition: Hypothyroidism Hypoparathyroidism | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002024-89 | Sponsor Protocol Number: 3475-177 | Start Date*: 2015-12-23 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | ||
Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) | ||
Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) DE (Completed) FI (Completed) SE (Completed) IE (Completed) DK (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001519-10 | Sponsor Protocol Number: ALN-GO1-008 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Di... | |||||||||||||
Medical condition: Recurrent calcium oxalate kidney stone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000411-40 | Sponsor Protocol Number: Version1.0 | Start Date*: 2015-10-23 |
Sponsor Name:Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg | ||
Full Title: Comparison of the detection of parathyroid adenoms using Tc-99m MIBI scintigraphy and F-18 Choline PET/CT in patients with primary hyperparathyroidism | ||
Medical condition: Primary hyperparathyroidism due to parathyroid adenoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004793-34 | Sponsor Protocol Number: P171103J | Start Date*: 2018-07-10 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: 68Ga-DOTATATE PET-CTA imaging for the early detection of progressing coronary atherosclerosis | ||
Medical condition: Patients with coronary atherosclerosis without significant myocardial ischemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004727-18 | Sponsor Protocol Number: CORUNO/II/05.1 | Start Date*: 2008-06-20 | |||||||||||
Sponsor Name:THERABEL PHARMACEUTICAL Ltd | |||||||||||||
Full Title: EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME. | |||||||||||||
Medical condition: Randomized, double-blind, placebo-controlled, add-on study in two parallel groups. Patients admitted for Non ST Segment Elevation Acute Coronary Syndromes will undergo a coronary angiography accord... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006210-14 | Sponsor Protocol Number: 20080579 | Start Date*: 2009-04-30 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastat... | |||||||||||||
Medical condition: Metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000274-36 | Sponsor Protocol Number: APACH2 | Start Date*: 2019-07-03 | |||||||||||
Sponsor Name:Centre François Baclesse | |||||||||||||
Full Title: Phase III trial comparing 2 diagnostic strategies for the preoperative localization of parathyroid adenoma in primary hyperparathyroidism: TEMP / CT with Tc99m-sestaMIBI or PET / CT with F18-choli... | |||||||||||||
Medical condition: Patient with primary hyperparathyroidism and for which surgical resection is provided. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004408-76 | Sponsor Protocol Number: 3475-585 | Start Date*: 2017-08-25 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subje... | |||||||||||||
Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) LT (Trial now transitioned) EE (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001816-56 | Sponsor Protocol Number: HUM 05-064 | Start Date*: 2006-05-11 |
Sponsor Name:Rigshospitalet | ||
Full Title: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? | ||
Medical condition: sarcoidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023120-24 | Sponsor Protocol Number: Nitro1 | Start Date*: 2011-10-18 | |||||||||||
Sponsor Name:MAASTRO clinic | |||||||||||||
Full Title: Nitroglycerin's effect on perfusion and hypoxia in human non small cell lung cancer: proof of principle, a phase II trial | |||||||||||||
Medical condition: non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000222-35 | Sponsor Protocol Number: 2017-000222-35 | Start Date*: 2017-07-21 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial | ||
Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011920-69 | Sponsor Protocol Number: 0822-043-00 | Start Date*: 2011-08-05 |
Sponsor Name:Merck & Co., Inc. | ||
Full Title: A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fra... | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002992-16 | Sponsor Protocol Number: EMN17/54767414MMY3014 | Start Date*: 2019-01-30 | |||||||||||
Sponsor Name:European Myeloma Network (EMN) | |||||||||||||
Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024624-20 | Sponsor Protocol Number: OCRD2010/22 | Start Date*: 2011-07-12 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | ||
Full Title: A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT | ||
Medical condition: Metastatic renal cell carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000767-17 | Sponsor Protocol Number: IRST100.22 | Start Date*: 2017-01-18 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) | |||||||||||||
Medical condition: Neuroendocrine Carcinomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001709-21 | Sponsor Protocol Number: 2020PI073 | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:CHRU de Nancy | |||||||||||||
Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis... | |||||||||||||
Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003577-26 | Sponsor Protocol Number: U1111-1131-5236 | Start Date*: 2012-10-24 |
Sponsor Name:Aarhus University Hospital | ||
Full Title: Liraglutide Kidney: A randomised, double-blinded, cross-over study investigating the short-term impact of liraglutide on kidney function in diabetic patients | ||
Medical condition: Type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016523-61 | Sponsor Protocol Number: PJMR0062105 | Start Date*: 2009-12-07 | |||||||||||
Sponsor Name:King’s College London [...] | |||||||||||||
Full Title: 18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation | |||||||||||||
Medical condition: Osteopenia Please note this is not a study to investigate the use of the IMP for the treatment of osteopenia but rather to validate a non-invasive imaging technique for measuring early changes in b... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002036-17 | Sponsor Protocol Number: NL61961.078.17 | Start Date*: 2018-03-06 | |||||||||||
Sponsor Name:Erasmus Medical Center | |||||||||||||
Full Title: THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER | |||||||||||||
Medical condition: (borderline) resectable pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
